A U.S. trade tribunal judge ruled that Apple’s redesigned smartwatches do not infringe on blood-oxygen patents held by Masimo. This preliminary decision rejects Masimo’s request for a new import ban on the devices.
The judge found that Apple’s modifications to the Apple Watch Series 9 and Ultra 2 successfully circumvented the disputed patents.
The U.S. International Trade Commission previously issued an import ban in 2023. This order forced Apple to briefly halt sales and remove the blood-oxygen feature from its devices.
The full commission will now review this preliminary finding to reach a final determination.